Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis. Issue 12 (16th December 2022)

• Record Type: Journal Article
• Authors: Hum, Ryan M; Kanigicherla, Durga A; Ho, Pauline
• Is Part Of: Oxford medical case reports. Volume 2022:Issue 12(2022)
• Publication Date: 2022-12-16
• Subjects: Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1093/omcr/omac133
• Languages: English
• ISSNs: 2053-8855

Abstract

ABSTRACT: We present a case of certolizumab-associated renal sarcoidosis, the first reported case in a patient with psoriatic arthritis (PsA) that was effectively treated with corticosteroids. A 55-year-old Caucasian man with PsA diagnosed at age 47 and plaque psoriasis since his early twenties was on certolizumab pegol (CZP) for 7 months before presenting to the emergency department with seizures and renal failure. A renal biopsy confirmed renal sarcoidosis. His CZP therapy was stopped, and after several months taking prednisolone at a reducing regime, his renal function improved, and his PsA remained under control. When considering further treatment options for his PsA keeping in mind that other drugs, especially tumour necrosis factor-alpha inhibitors, have been reported to be associated with sarcoidosis, tofacitinib was considered to be a future treatment option acceptable to the patient, given current National Institute for Health and Care Excellence guidelines approving its use in PsA and the lack of reports of tofacitinib-associated sarcoidosis in the literature.